CD274 and hepatocellular carcinoma: In conclusion, combining PD-1/PD-L1 inhibitors and bevacizumab as the first-line treatment can improve the curative effect in patients with advanced HCC, and FDA-approved atezolizumab plus bevacizumab for patients with advanced HCC who had not received prior systemic therapy and whether PD-L1 is positive or not in these patients.